Vtv Therapeutics Inc- Cl A (VTVT) Institutional Buying & Selling Tracker (Q2 2026)

VTVT ranks #6440 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

VTVT is a disclosed holding of Israel Englander (Millennium Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

45 institutions disclose a position in VTVT, but none treat it as a major bet — even Samsara BioCapital, LLC, its most concentrated holder, allocates just 0.9% of its own portfolio to it.

BlackRock has added to its VTVT position for two straight quarters, increasing it by $130.5K to reach $554.6K today.

Trails Edge Capital Partners, LP has trimmed its VTVT position for two straight quarters, cutting it by $6.0M while still holding $3.2M.

VTVT is up 4.5% today, and institutions have been net buyers of $6.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

VTVT reported a net loss of $4.8M over the trailing twelve months.

• Not yet profitable — net loss of $4.8M over the trailing twelve months
• Revenue grew 216600.0% year over year
• Net income improved year over year, from -$19.6M to -$4.8M
• Operating cash flow was negative, using $25.3M in cash
• Current ratio of 13.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.40x equity — within a conventional range